Advances in Radiation Therapy Enhancement and Radio-Protection By Nano-Curcumins: A Systematic Review
Abstract
Introduction/objective: Nano-curcumins (Nano-CUR) improve solubility, bioavailability, and stability of the release of CUR into the body. In this systematic review, we aim to investigate different CUR nanoformulations' in targeting radiosensitizing pathways and radioprotective mechanisms.
Methods: We thoroughly searched electronic databases, including PubMed/MEDLINE, Web of Science, Scopus, Embase, and Cochrane Library to identify pertinent studies published before July 21, 2024. inclusion and exclusion criteria were set based on the study's purposes. Two reviewers independently performed data extraction to ensure precision and minimize bias. Subsequently, the data were extracted and analyzed.
Results: A total of 24 articles were included. Nano-CURs by scavenging the levels of reactive oxygen species (ROS), decrease malondialdehyde (MDA), improve superoxide dismutase (SOD), prevent DNA methylation, reduce tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-b and transforming growth factor-beta (TGF-β1), improve cell cycle, inhibit vascular endothelial growth factor (VEGF), attenuate cell cytotoxicity and modulate cell apoptosis induce its radioprotective effects. In contrast, Nano-CUR induces oxidative stress and accumulation ROS, inhibits nuclear factor-κB (NF- κB), activates the expression of TNF, TGF-β, phosphatidylinositol and FoxO, causing DNA damage, activating proapoptotic pathways (boosted P53, P21 and BAX expressions), cell cycle arrest, reducing…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.